Comparative Pharmacology
Head-to-head clinical analysis: CODIMAL L A 12 versus CODRIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CODIMAL L A 12 versus CODRIX.
CODIMAL-L.A. 12 vs CODRIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codimal-L.A. 12 contains chlorpheniramine, a histamine H1 receptor antagonist, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors. Chlorpheniramine competitively blocks histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine causes vasoconstriction via alpha-1 adrenergic receptor activation, leading to nasal decongestion.
Codrix is a combination of codeine (a mu-opioid receptor agonist) and paracetamol (cyclooxygenase inhibitor, primarily in the CNS). Codeine is metabolized to morphine via CYP2D6, which mediates opioid effects. Paracetamol inhibits prostaglandin synthesis, providing analgesic and antipyretic effects.
One tablet orally every 12 hours. Each tablet contains 25 mg phenylpropanolamine HCl and 4 mg chlorpheniramine maleate.
2 mg orally once daily.
None Documented
None Documented
12 hours (terminal); supports once-daily dosing, steady-state in 2-3 days.
Terminal half-life 12-15 hours; steady-state reached in 2-3 days.
Renal: 90% (unchanged drug). Biliary/fecal: <10%.
Primarily renal (60% unchanged) and biliary/fecal (30%); 10% metabolized.
Category C
Category C
Cold & Cough Combination
Cold & Cough Combination